Chart: Sponsors Go 2 For 4 At ODAC With Pazdur On The Mound
Executive Summary
An extended baseball analogy by some committee members is as close as sponsors came to hitting anything out of the park during the Sept. 1-2 meeting of FDA's Oncologic Drugs Advisory Committee. ODAC agreed with FDA that randomized controlled trials - which none of the four drugs reviewed had - were needed for approval, but members were less adamant about that principle when applying it might mean leaving patients on base.
You may also be interested in...
Cancer Drug Clinical Trial Endpoints Should Consider Quality-Of-Life PROs, Advocate Says
Former FDA advisory committee patient representative petitions agency to require comparison of quality of life-related patient reported outcomes for surrogate endpoints, including progression-free survival.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials